39,965 Shares in Insulet Corporation $PODD Acquired by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company bought a new position in shares of Insulet Corporation (NASDAQ:PODD) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 39,965 shares of the medical instruments supplier’s stock, valued at approximately $6,085,000. The Manufacturers Life Insurance Company owned about 0.06% of Insulet as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Larson Financial Group LLC grew its holdings in shares of Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 47 shares during the period. University of Texas Texas AM Investment Management Co. acquired a new position in Insulet in the fourth quarter valued at about $26,000. DV Equities LLC acquired a new position in Insulet in the fourth quarter valued at about $28,000. Elyxium Wealth LLC purchased a new position in Insulet during the fourth quarter worth about $28,000. Finally, Mcguire Capital Advisors Inc. purchased a new position in Insulet during the fourth quarter worth about $29,000.

Insulet Price Performance

Shares of PODD opened at $148.66 on Tuesday. Insulet Corporation has a fifty-two week low of $126.40 and a fifty-two week high of $354.88. The firm’s 50 day moving average price is $154.65 and its 200 day moving average price is $179.96. The company has a market cap of $10.31 billion, a P/E ratio of 27.79, a PEG ratio of 1.14 and a beta of 1.10. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. The company had revenue of $801.70 million for the quarter, compared to analyst estimates of $787.39 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The firm’s quarterly revenue was up 23.5% on a year-over-year basis. During the same period in the prior year, the business earned $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, research analysts forecast that Insulet Corporation will post 6.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on PODD. Oppenheimer downgraded shares of Insulet from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 5th. Royal Bank Of Canada dropped their target price on shares of Insulet from $245.00 to $160.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Wells Fargo & Company lowered Insulet from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $255.00 to $144.00 in a research report on Wednesday, August 5th. JPMorgan Chase & Co. restated a “neutral” rating and set a $152.00 price target (down from $275.00) on shares of Insulet in a research note on Thursday, August 6th. Finally, Stifel Nicolaus lowered their price target on Insulet from $225.00 to $180.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Fourteen analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $195.40.

Insulet News Summary

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s most recent quarterly results provide a favorable fundamental backdrop: revenue rose 23.5% year over year to $801.7 million and adjusted earnings of $1.66 per share exceeded consensus expectations of $1.47. This strength may be helping offset concerns related to the lawsuit.
• Neutral Sentiment: Multiple investor-rights firms—including Faruqi & Faruqi, Rosen, Bronstein Gewirtz & Grossman, Levi & Korsinsky, and others—are soliciting affected shareholders ahead of the August 31, 2026 lead-plaintiff deadline. The announcements largely repeat the same litigation information rather than representing separate lawsuits or new company disclosures. Faruqi securities class-action deadline notice
• Negative Sentiment: The filed class action alleges that Insulet and certain officers violated federal securities laws by making misleading statements or failing to disclose material information. One notice specifically points to alleged manufacturing problems at the company’s Acton facility, including medical-device corrections affecting millions of Pods, despite SEC filings that described quality-assurance inspections during manufacturing. The allegations have not been proven, but potential damages, legal costs, reputational harm, and further regulatory or operational consequences could pressure valuation. Bronstein class-action announcement Levi and Korsinsky lawsuit notice

Insider Activity

In related news, Director Timothy C. Stonesifer bought 2,790 shares of the firm’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was purchased at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the acquisition, the director owned 9,041 shares in the company, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.36% of the company’s stock.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.